Veteran CFO appointment underscores the Company’s commitment to building a strong leadership team as it advances its clinical and commercial strategyTEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. M ...